In this issue:
Safety of guselkumab in TNFI-naïve/ experienced PsA patients
Association between visceral fat and disease activity
Impact of alexithymia in axSpA patients
Supervised exercise and AS symptoms
Safety and efficacy of risankizumab
Alleviating depressive symptoms in SpA
Agreement between clinical diagnoses and criteria
Costovertebral joint association with axSpA
Axial damage of sacroiliac joints and spine in PsA and SpA patients
Ixekizumab therapy after secukinumab failure
Please login below to download this issue (PDF)